Next Article in Journal
Selenium and Metabolic Disorders: An Emphasis on Type 2 Diabetes Risk
Previous Article in Journal
High Prevalence of Vitamin D Deficiency among Pregnant Saudi Women
Article Menu

Export Article

Open AccessReview
Nutrients 2016, 8(2), 76;

Exogenous Glutamine in Respiratory Diseases: Myth or Reality?

Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Centro de Ciências da Saúde, Av. Carlos Chagas Filho, 373, Bloco G-014, Ilha do Fundão, Rio de Janeiro, RJ 21941-902, Brazil
Department of Anesthesiology and Intensive Care Therapy, Pulmonary Engineering Group, University Hospital Carl Gustav Carus, Technische Universität, Fetscherstrasse 74, 01307 Dresden, Germany
Department of Surgical Sciences and Integrated Diagnostics, Istituto di Ricovero e Cura a Carattere Scientifico, Research Hospital (IRCCS AOU), San Martino Istituto Nazionale Tumori, National Cancer Institute (IST), University of Genoa, 16132 Genoa, Italy
Author to whom correspondence should be addressed.
Received: 30 November 2015 / Revised: 20 January 2016 / Accepted: 26 January 2016 / Published: 4 February 2016
Full-Text   |   PDF [731 KB, uploaded 4 February 2016]   |  


Several respiratory diseases feature increased inflammatory response and catabolic activity, which are associated with glutamine depletion; thus, the benefits of exogenous glutamine administration have been evaluated in clinical trials and models of different respiratory diseases. Recent reviews and meta-analyses have focused on the effects and mechanisms of action of glutamine in a general population of critical care patients or in different models of injury. However, little information is available about the role of glutamine in respiratory diseases. The aim of the present review is to discuss the evidence of glutamine depletion in cystic fibrosis (CF), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and lung cancer, as well as the results of exogenous glutamine administration in experimental and clinical studies. Exogenous glutamine administration might be beneficial in ARDS, asthma, and during lung cancer treatment, thus representing a potential therapeutic tool in these conditions. Further experimental and large randomized clinical trials focusing on the development and progression of respiratory diseases are necessary to elucidate the effects and possible therapeutic role of glutamine in this setting. View Full-Text
Keywords: glutamine; cystic fibrosis; asthma; chronic obstructive pulmonary disease; acute respiratory distress syndrome; lung cancer glutamine; cystic fibrosis; asthma; chronic obstructive pulmonary disease; acute respiratory distress syndrome; lung cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Oliveira, G.P.; de Abreu, M.G.; Pelosi, P.; Rocco, P.R.M. Exogenous Glutamine in Respiratory Diseases: Myth or Reality? Nutrients 2016, 8, 76.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top